Company overview
bit.bio is a synthetic biology company providing human iPSC-derived cells for research, drug discovery, and cell therapy applications. They utilize patented opti-ox™ technology to deterministically reprogram stem cells into consistent, scalable cell types such as neurons, immune cells, and muscle cells under the ioCells brand. Their platform supports neurodegeneration, neurophysiology, and disease modeling with reliable, high-quality human cells.
bit.bio is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include bit.bio, ipsc-derived cells, human neurons, opti-ox technology, drug discovery cells.
Structured facts
- Website
- https://www.bit.bio
- Markets served
- United States & Americas
- Keywords
- bit.bio, ipsc-derived cells, human neurons, opti-ox technology, drug discovery cells
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What cell types does bit.bio offer?
- bit.bio offers human iPSC-derived neurons (including glutamatergic, GABAergic, and motor neurons), immune cells, muscle cells, and disease models under the ioCells brand for research and drug discovery.
- What is bit.bio's core technology?
- bit.bio's opti-ox™ technology enables deterministic, precise reprogramming of human iPSCs into defined cell types using inducible transcription factors discovered via their genetic screening and machine learning platform.
- What are the applications of bit.bio's products?
- Products support neurodegeneration, neurophysiology, neurodevelopmental research, drug discovery, and cell therapy with consistent, scalable human cells to reduce experimental variance.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
